AGEN Agenus (AGEN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001098972
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
AGEN filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by ZYNEXT VENTURES USA LLC, filed 2026-01-23, for 5.9% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Agenus insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for AGENUS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Sep 13, 2021.
- The trade is 79.9% of the 625,969 shares held after it.
- No other insider bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: See Remarks ARMEN GARO H bought about $325.0K of AGEN on Feb 15, 2024, the largest insider purchase at the company on our record; 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 20.2% of the 124,063 shares held after it.
- No other insider bought within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WIINBERG ULF bought about $19.0K of AGEN on Nov 15, 2023, the largest insider purchase at the company on our record; 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 63.1% of the 61,321 shares held after it.
- No other insider sold within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer O'Day Steven J sold about $118.4K of AGEN on Jan 6, 2022; 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 10.7% of the 770,773 shares held after it.
- 1 other insider sold within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO ARMEN GARO H sold about $533.7K of AGEN on Sep 13, 2021, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 64 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 11.9% of the 93,056 shares held after it.
- 1 other insider sold within 30 days.
- 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: PFO & PAO KLASKIN CHRISTINE M sold about $72.3K of AGEN on Sep 10, 2021, the largest insider sale at the company on our record; 1 other insider sold within 30 days and 64 funds added in the latest 13F quarter.5 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
+10.4% year over year
more than 60% of Pharma & Biotech
Margin
-2.7% net margin
more than 71% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
17.4% of the float short (float per yahoo 2026-10-27) · 6.5 days to cover · settled 2026-10-15
more than 86% of Pharma & Biotech
The situation: each line is one rule over one dataset
1 clinical trial was terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch AGEN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+59.1%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns AGEN: institutional holders (13F)
13F holdings, latest reported quarter
2,564,884 sh
$7.8M
1,676,096 sh
$5.1M
1,427,587 sh
$4.4M
1,064,250 sh
$3.3M
1,035,040 sh
$3.2M
Congress trades in AGEN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
ZYNEXT VENTURES USA LLC
Activist 13D · 2026-01-23
5.9%
ZYNEXT VENTURES PTE LTD
Activist 13D · 2026-01-23
5.9%
ZYDUS LIFESCIENCES LTD
Activist 13D · 2026-01-23
5.9%
AGEN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
AGEN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
SIIT SMALL CAP II FUND
$296.4K position · as of 2026-05-31
0.1%
ACUITAS US MICROCAP FUND
$139.2K position · as of 2026-06-30
0.1%
PGIM Quant Solutions Small-Cap Value Fund
$296.2K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$410.0K position · as of 2026-06-30
0.0%
SMALL COMPANY GROWTH PORTFOLIO
$351.1K position · as of 2026-06-30
0.0%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND
$628.4K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
15 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
4
Phase 1
1 active
6
Phase 2
1 active
2
Not applicable
0 active
3
Multi-phase
0 active
What changed recently
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
2026-10-20 · Active Not Recruiting → Terminated · Sponsor decision
Phase 2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$1.4M
$3.6M
$617.4K
-93%
n/a
2024
$4.1M
$2.9M
$926.9K
-97%
n/a
2023
$5.9M
-$1.5M
$1.1M
-80%
n/a
2022
$5.6M
-$1.7M
$969.7K
-41%
+11%
2021
$9.8M
$8.6M
$2.8M
-21%
+25%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 64 funds added last quarter. Each figure is a federal filing, dated the day it went public.
AGEN financials
Revenue growth
+10.4%
XBRL, annual
Net margin
-2.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$132.7M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM AGEN
| FY Dec 2025 | $114.2M |
| FY Dec 2024 | $103.5M |
| FY Dec 2023 | $156.3M |
| FY Dec 2022 | $98.0M |
| FY Dec 2021 | $295.7M |
| Jun 2026 | $34.5M |
| Mar 2026 | $33.7M |
| Dec 2025 | $34.2M |
| Sep 2025 | $30.2M |
| Jun 2025 | $25.7M |
| Mar 2025 | $24.1M |
| Dec 2024 | $26.8M |
| Sep 2024 | $25.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+69.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM AGEN
| FY Dec 2025 | -2.7% |
| FY Dec 2024 | -224.5% |
| FY Dec 2023 | -164.7% |
| FY Dec 2022 | -235.3% |
| FY Dec 2021 | -9.7% |
| Jun 2026 | -1.6% |
| Mar 2026 | +116.2% |
| Dec 2025 | -31.0% |
| Sep 2025 | +211.4% |
| Jun 2025 | -116.8% |
| Mar 2025 | -109.6% |
| Dec 2024 | -174.4% |
| Sep 2024 | -267.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$98.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM AGEN
| FY Dec 2025 | -$77.2M |
| FY Dec 2024 | -$158.9M |
| FY Dec 2023 | -$234.2M |
| FY Dec 2022 | -$228.4M |
| FY Dec 2021 | -$23.7M |
| Jun 2026 | -$31.2M |
| Mar 2026 | -$36.0M |
| Dec 2025 | -$16.6M |
| Sep 2025 | -$14.7M |
| Jun 2025 | -$20.2M |
| Mar 2025 | -$25.6M |
| Dec 2024 | -$28.7M |
| Sep 2024 | -$53.3M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.39x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.28x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt AGEN
| FY Dec 2025 | -1.73x |
| FY Dec 2024 | -4.77x |
| FY Dec 2023 | -17.36x |
| FY Dec 2022 | -13.33x |
| FY Dec 2021 | 0.75x |
| Jun 2026 | -3.28x |
| Mar 2026 | -2.90x |
| Dec 2025 | -1.73x |
| Sep 2025 | -2.61x |
| Jun 2025 | -3.77x |
| Mar 2025 | -4.34x |
| Dec 2024 | -4.77x |
| Sep 2024 | -12.69x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+51.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets AGEN
| FY Dec 2025 | -1.4% |
| FY Dec 2024 | -86.0% |
| FY Dec 2023 | -70.8% |
| FY Dec 2022 | -52.5% |
| FY Dec 2021 | -8.4% |
| Jun 2026 | +51.4% |
| Mar 2026 | +32.3% |
| Dec 2025 | -1.4% |
| Sep 2025 | -16.6% |
| Jun 2025 | -71.4% |
| Mar 2025 | -85.5% |
| Dec 2024 | -86.0% |
| Sep 2024 | -81.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | -383.2% |
| FY Dec 2023 | -112.9% |
| FY Dec 2022 | -67.2% |
| FY Dec 2021 | +13.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -383.2% |
| Sep 2024 | -188.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
2.58x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 1.19x |
| Mar 2026 | 2.10x |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$310.7M
market value at close 2026-10-27 on 2026-08-04 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value AGEN
| FY Dec 2025 | $148.4M |
| FY Dec 2024 | $57.0M |
| FY Dec 2023 | $6.3B |
| FY Dec 2022 | $14.2B |
| FY Dec 2021 | $16.0B |
| Jun 2026 | $138.8M |
| Mar 2026 | $123.4M |
| Dec 2025 | $148.4M |
| Sep 2025 | $153.4M |
| Jun 2025 | $149.6M |
| Mar 2025 | $53.3M |
| Dec 2024 | $57.0M |
| Sep 2024 | $86.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-32.9%
TTM free cash flow over market value at close 2026-10-27
FCF yield AGEN
| FY Dec 2025 | -72.3% |
| FY Dec 2024 | -247.2% |
| FY Dec 2023 | -3.7% |
| FY Dec 2022 | -1.6% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | -77.3% |
| Mar 2026 | -68.2% |
| Dec 2025 | -72.3% |
| Sep 2025 | -72.8% |
| Jun 2025 | -102.1% |
| Mar 2025 | -382.8% |
| Dec 2024 | -247.2% |
| Sep 2024 | -144.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing AGEN
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $114.2M | $103.5M | $156.3M | $98.0M |
| Operating income | -$20.2M | -$120.5M | -$159.5M | -$179.4M |
| Net income | -$3.1M | -$232.3M | -$257.4M | -$230.7M |
| EPS (diluted) | 0.00 | -10.59 | -13.75 | -15.64 |
| Operating cash flow | -$77.2M | -$158.3M | -$224.2M | -$175.4M |
| Cash | $3.0M | $40.4M | $76.1M | $178.7M |
| Long-term debt | $0 | $30.5M | $12.8M | $12.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
AGEN Stock Sonar score 4/7 axes
Find similar shapesCompareAGEN ranks highest on growth (60th percentile) and risk and compliance (54th), and lowest on financial health (36th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
